Real-World Effects and Utilisation Patterns of Elexacaftor, Tezacaftor, and Ivacaftor Combination Therapy (ELX/TEZ/IVA) in Patients with Cystic Fibrosis (CF)

First published 15/09/2021

Last updated 03/03/2025

EU PAS number:

EUPAS43022

Study

Ongoing

Documents

Study protocol

Initial protocol

ELX-TEZ-IVA PASS Protocol_Version 2.0_redacted

English (674.84 KB - PDF) View document

Study results

Study report

Other information

Secondary tabs